Utiliza este identificador para citar o vincular este elemento: http://hdl.handle.net/10553/35488
Títulos: Tyrosinemia type II: Mutation update, 11 novel mutations and description of 5 independent subjects with a novel founder mutation
Autores/as: Peña Quintana, Luis 
Scherer, G.
Curbelo-Estévez, M. L.
Jimenez Acosta, Francisco 
Hartmann, B.
La Roche, F.
Meavilla-Olivas, S.
Pérez-Cerdá, C.
García-Segarra, N.
Giguere, Y.
Huppke, P.
Mitchell, G. A.
Moench, E.
Trump, D.
Vianey-Saban, C.
Trimble, E. R.
Vitoria-Minana, I.
Reyes Suárez, D. 
Ramírez Lorenzo, Mª Teresa
Tugores, Antonio 
Clasificación UNESCO: 32 Ciencias médicas
Palabras clave: Genetics
Richner-Hanhart
TAT
Tyrosinemia
Fecha de publicación: 2017
Revistas: Clinical Genetics 
Resumen: Background: Tyrosinemia type II, also known as Richner-Hanhart Syndrome, is an extremely rare autosomal recessive disorder, caused by mutations in the gene encoding hepatic cytosolic tyrosine aminotransferase, leading to the accumulation of tyrosine and its metabolites which cause ocular and skin lesions, that may be accompanied by neurological manifestations, mostly intellectual disability. Aims: To update disease-causing mutations and current clinical knowledge of the disease. Materials and Methods: Genetic and clinical information were obtained from a collection of both unreported and previously reported cases. Results: We report 106 families, represented by 143 individuals, carrying a total of 36 genetic variants, 11 of them not previously known to be associated with the disease. Variants include 3 large deletions, 21 non-synonymous and 5 nonsense amino-acid changes, 5 frameshifts and 2 splice variants. We also report 5 patients from Gran Canaria, representing the largest known group of unrelated families sharing the same P406L mutation. Conclusions: Data analysis did not reveal a genotype-phenotype correlation, but stressed the need of early diagnosis: All patients improved the oculocutaneous lesions after dietary treat- ment but neurological symptoms prevailed. The discovery of founder mutations in isolated populations, and the benefits of early intervention, should increase diagnostic awareness in newborns.
URI: http://hdl.handle.net/10553/35488
ISSN: 0009-9163
DOI: 10.1111/cge.13003
Aparece en la colección:Artículos

Muestra el registro completo del elemento

Citas SCOPUSTM   

2
actualizado el 26-nov-2018

Citas de WEB OF SCIENCETM
Citations

2
actualizado el 03-ene-2019

Vista de página(s)

3
actualizado el 04-ene-2019

Google ScholarTM

Verifica

Altmetric


Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor, con todos los derechos reservados, a menos que se indique lo contrario.